Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions

Cristiana Forni, Stefano Ferrari, Loretta Loro, Teresa Mazzei, Claudio Beghelli, Angela Biolchini, Patrizia Simoni, Morena Tremosini, Sergio Strazzari, Cristina Puggioli, Gaetano Bacci

Research output: Contribution to journalArticle

Abstract

The antiemetic efficacy of granisetron, ondansetron and tropisetron was evaluated in patients treated with cisplatin-Adriamycin (CDP/ADM) and ifosfamide (IFO) by continuous infusion (CI). In all, 90 patients with osteosarcoma were randomly assigned to receive granisetron (2 mg/m2), or ondansetron (5.3 mg/m2), or tropisetron (3.3 mg/m2) plus dexamethasone 8 mg/m2. Chemotherapy consisted of CDP (120 mg/m2, 48-h CI) followed by ADM (75 mg/m2, 24-h CI) and then, in the second cycle, delivered 3 weeks later, IFO 15 g/m2 (120-h CI). Complete protection (CP) from emesis was obtained on 59% of the 717 days of treatment, without significant differences among the three study drugs. A significantly higher rate of CP was obtained during chemotherapy with IFO than with CDP/ADM (69% vs 44%; P

Original languageEnglish
Pages (from-to)131-133
Number of pages3
JournalSupportive Care in Cancer
Volume8
Issue number2
Publication statusPublished - Mar 2000

Keywords

  • Continuous infusion
  • Emesis
  • Granisetron
  • Ondansetron
  • Tropisetron

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Fingerprint Dive into the research topics of 'Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions'. Together they form a unique fingerprint.

  • Cite this

    Forni, C., Ferrari, S., Loro, L., Mazzei, T., Beghelli, C., Biolchini, A., Simoni, P., Tremosini, M., Strazzari, S., Puggioli, C., & Bacci, G. (2000). Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. Supportive Care in Cancer, 8(2), 131-133.